excipients fpr lipid formulations_aapsworkshop

33
1 Colin W. Pouton Victorian College of Pharmacy, Monash University, Melbourne, Australia E-mail: [email protected] Phone: + 61 3 9903 9562 Properties and Uses of Common Formulation Lipids, Surfactants and Cosolvents AAPS Workshop March 2007

Upload: baharnarenj11

Post on 28-Mar-2015

743 views

Category:

Documents


3 download

TRANSCRIPT

Page 1: Excipients fpr lipid formulations_AAPSWorkshop

1

Colin W. Pouton

Victorian College of Pharmacy, Monash University, Melbourne, Australia

E-mail: [email protected]

Phone: + 61 3 9903 9562

Properties and Uses of Common Formulation

Lipids, Surfactants and Cosolvents

AAPS Workshop March 2007

Page 2: Excipients fpr lipid formulations_AAPSWorkshop

2

Excipients for lipid formulations

Hydro

phobic

Hydro

philic

liquids waxes

mineral oils petrolatumvegetable oils hydrogenated vegetable oilsMCT oil, diglycerides monoglycerides

glyceryl mono-oleate glyceryl mono-stearatesorbitan oleates (Spans 80, 85) sorbitan stearateesters

POE-oleate estersPOE triglceridespolysorbate 85 POE hydrogenated veg oils

polysorbate 80, Cremophor EL polysorbate 20

PEG 400, propylene glycol PEG > 1500

Page 3: Excipients fpr lipid formulations_AAPSWorkshop

3

General Issues in excipient selection

• Regulatory issues – irritancy, toxicity, knowledge and experience

• Solvent capacity

• Miscibility

• Morphology at room temperature (i.e. melting point)

• Self-dispersibility and role in promoting self-dispersion of the formulation

• Digestibility, and fate of digested products

• Capsule compatibility

• Purity, chemical stability

Page 4: Excipients fpr lipid formulations_AAPSWorkshop

4

Regulatory Issues in excipient selection

• Amongst typical excipients for lipid materials surfactants cause the most concern

• Hydrophobic surfactants can penetrate membranes causing changes in membrane fluidity and permeability. Generally singlealkyl chains are more penetrative, so bulky surfactants such as polysorbates and triglyceride ethoxylates are less ‘toxic’

• Hydrophilic surfactants can extract lipids into the aqueous phase and destroy membranes.

• In animal toxicity studies – cationics > anionics > nonionics

• Toxicity of nonionics – single chain ethers > single chain esters > bulky esters (most commonly used are bulky esters)

• Acute LD50 values for nonionics in rodents are 5-10 g/kg (IV), >50g/kg (oral). Some chronic studies are available for a wide variety of surfactants (see textbooks of Schick, and Attwood and Florence)

Page 5: Excipients fpr lipid formulations_AAPSWorkshop

5

Regulatory Issues in excipient selection – in practice

• Animal data suggests that most nonionic surfactants are equal – but in practice some are more equal than others!

• The choice of surfactants is often driven by prior use in existing food and pharmaceutical products, for fear of failure late in toxicity tests

• Food substances classed as GRAS (generally recognized as safe) will be favoured

• The US FDA Center for Drug Evaluation and Research has now posted a database of excipients – the ‘Inactive Ingredients Database’ which states the masses or concentrations of ingredients used in marketed pharmaceutical products (see www.fda.gov/cder)

• To use a new excipient may imply a cost of about $20 million for full toxicity evaluation - a new draft guidance document is posted at cder website (see www.fda.gov/cder/guidance/3812dft.doc)

• The inactive ingredients database will be a major driver in the future

Page 6: Excipients fpr lipid formulations_AAPSWorkshop

6

Capsule compatibility

• Lipid systems can be filled into soft or hard gelatin providing an effective sealing system is available for hard gelatin

• Maintaining water in formulations is difficult – note that water moves into and out of softgel capsules. w/o emulsions and microemulsionscan lose water quickly during drying of softgels.

• Other low molecular weight polar compounds (eg propylene glycol)can cause compatibility problems at high concentration

• Virtue of working with capsule filling companies is to access the wealth of knowledge on gelatin formulation and excipient compatibility

• Soft and hard gel manufacturers are working hard to improve compatibility and move to non-animal sources for capsule shell materials

Page 7: Excipients fpr lipid formulations_AAPSWorkshop

7

Miscibility of excipients

• Oils and cosolvents are generally not miscible, but the inclusion of polar oils (such as mono and diglycerides) or surfactants createsingle phase solutions.

Page 8: Excipients fpr lipid formulations_AAPSWorkshop

8

Solubility in lipid formulations

Take care to ensure solubility measurements in oily formulations are reliableAlways have crystalline solid present in excess – leave enough time for equilibration

In the experiment below testosterone was mixed with a lipid formulation at thetemperature shown then allowed to equilibrate at 25oC over a week

Page 9: Excipients fpr lipid formulations_AAPSWorkshop

9

Waxy versus liquid excipients

• Esters with saturated alkyl chains >C12 tend to crystallize at ambient temperatures

• Monoglycerides crystallize at higher temps than di- or triglycerides

• Hydrophilic surfactants with high PEG content tend to be waxy, unless unsaturatedglycerides are predominant

• Liquid formulations are desirable to avoid morphological changes due to crystallization during storage – but beware of slow crystallization if close to a phase boundary

• ‘Solid solutions’ could allow presentation of the drug in an amorphous form but are at risk of re-crystallization

Typical liquid excipients

• medium chain di and triglycerides (monoglycerides are crystalline but blends with diand triglycerides are liquid)

• unsaturated long-chain triglycerides (typical vegetable oils) and hydrolysed oils as long as the monoglyceride content is low (NB - consider Maisine)

• unsaturated or medium chain ethoxylates (eg. polysorbate 80, Labrasol)

Page 10: Excipients fpr lipid formulations_AAPSWorkshop

10

Lipids

• ‘Pure’ lipids relatively easy to classify

• Typically glycerides derived from plants

• Most simply triglycerides, but also more polar mono and di-glycerides

• Fatty acids also occasionally used, although possible problems with stability (esterification) and irritancy (especially with shorter chain lipids)

• Key issues for glycerides are residual fatty acids

• Several providers of refined or super-refined lipids, usually more specific wrt fatty acid chain lengths/unsaturation, and or residual fatty acid

Page 11: Excipients fpr lipid formulations_AAPSWorkshop

11

Fatty acid composition of common oils

0.228.364.21.0Apricot kernel

45.041.04.09.0Sesame

2.015.03.08.016.048.04.0Palm kernel

036.048.04.012.0Peanut

87

C18:1 - OH

3.07.01.02.0Castor

0.267.920.73.56.2Sunflower

7.851.521.53.510.4Soybean

0.481.411.11.65.5Safflower

10.040.04.045.01.0Palm

0.910.771.22.012.9Olive

1.161.324.51.610.7Corn

03.117.82.89.616.644.42.72.4Coconut

9.121.760.02.04.7Canola

C18:3C18:2C18:1C18C16C14C12C10C8Oil

Page 12: Excipients fpr lipid formulations_AAPSWorkshop

12

Polar Lipids

• e.g. lipids such as monoglycerides, propylene glycol esters and diesters, and sorbitan esters

• these materials typically are poorly soluble in water but have free hydroxyl groups which can hydrogen bond with water, surfactants, cosolvents etc.

• polar lipids typically are better solvents for drugs

• polar lipids act as ‘co-surfactants’ which promote mutual solubility between excipients, enhance water uptake, and promote self-dispersibility of lipid formulations

• Polar lipids are vital components of Type II and Type III lipid formulations

Page 13: Excipients fpr lipid formulations_AAPSWorkshop

13

Medium Chain Triglycerides

• Triglycerides of fractionated vegetable C8 and C10 fatty acids (usually fractionated coconut oil). Several manufacturers produce MCTs which meet USP/EP spec.

• Saturated, stable, liquids, good solvent properties

• Miglyol 810/812

– 810 C8 (65-80%); C10 (20-35%)

– 812 C8 (50-65%); C10 (30-45%)

• Captex 300, 355, Neobee M5, Crodamol GTC/C

• Labrafac Lipophile WL 1349 (EP/USP Spec)

– C8 (50-80%); C10 (20-50%); C12 (<3%)

• Also variations on a theme with slightly differing FA proportions

– Miglyol 818 C8 (45-65%); C10 (30-45%); C18:2 (2-5%)

– Captex 810D C8-10 (max 40%); C18:2 (max 40%)

Page 14: Excipients fpr lipid formulations_AAPSWorkshop

14

Medium Chain Mono and Diglycerides

Usually mono and diglycerides of capric (C10) and caprylic (C8) FA, with traces of TG

• Capmul (Abitec)

– Capmul MCM (58% MG, 36% DG, 5% TG; 80% C8, 20% C10)

– Capmul MCM C8 (68% MG, 27% DG, 3% TG; >95% C8, 3% C10; )

– Capmul MCM C10 (> 45% MG; >45% C10)

• Imwitor (Sasol)

– Imwitor 988 (MG/DG/TG of primarily caprylic (C8) acid; 47-57% MG)

– Imwitor 742 (MG/DG/TG of C8 and C10 FA; 45-55% MG)

– Imwitor 928 (MG/DG/TG of saturated FA of coconut oil (mainly C12)

min 40% MG)

Page 15: Excipients fpr lipid formulations_AAPSWorkshop

15

Long Chain Mono and Diglyceride blends

• Typically a mixture of MG, DG and smaller quantities of TG

• Typical products:

– Peceol: Glyceryl monooleate HLB 3.3 Glyceride content: MG: 32-52%; DG 30-50%; TG: 5-20%

FA Composition: C18:1>60%; C18:2<35%; C18:0<6%; C16<12%0-5%

– Maisine 35-1: Glyceryl monolinoleate HLB = 4

Glyceride content: MG: 32-52%, DG: 40-55%, TG 5-20%

FA Composition: C18:2 >50% max; C18:1 10-35%; C18:0 <6%; C16 4-20%

Page 16: Excipients fpr lipid formulations_AAPSWorkshop

16

Propylene glycol esters

O

Name R (fatty acid)

> 90% Monoester of C8 (caprylic

acid)

6

Capryol 90

Propylene glycol monocaprylate 90%

HLB

> 60% Monoester

> 90% C8

5

Capryol PGMC

Propylene glycol caprylate

C10/C12 2

Labrafac PG

Propylene glycol dicaprylocaprate

Note

V low HLB, actually functions as lipophilic solvent cfMCT

R-C-O-CH2CHOH-CH3

Possible effects on P-gp (poster

#T3124, AAPS 05)

Page 17: Excipients fpr lipid formulations_AAPSWorkshop

17

Propylene glycol esters: Lauroglycol

R-C-O-CH2CHOH-CH3

O

Name R (fatty acid) HLB

> 90% Monoester > 95% C12 (lauricacid)

5

Lauroglycol 90

Propylene glycol monolaurate

45-70% Monoester30-55% Diester> 95% C12

4

Lauroglycol FCC

Propylene glycol laurate

Page 18: Excipients fpr lipid formulations_AAPSWorkshop

18

Notes on surfactants, cosurfactants for lipid formulations

• Cremophors (castor oil ethoxylates), Gelucires, Labrosol are remarkably good for SMEDDS formulations with no apparent advantage of unsaturation (ie. Cremophor EL versus RH40).

• Polar oils (eg. MGs, DGs, oleic acid) are critical components of many formulations. They promote water penetration and have good solvent capacity for drugs. Choice of medium chain or long chain materials is influenced by several considerations:

- medium chain glycerides are better solvents, not prone to oxidation

- digestion products of long chain glycerides may be beneficial

- MGs are more crystalline: glyceryl monooleate is semi-solid

• Surfactants with high ethoxylate content are waxy

• Digestibility of surfactants may have a critical influence – more work is needed in this area (ethers versus esters, effect of concentration)

• Some unusual surfactants have become popular (TPGS)

Page 19: Excipients fpr lipid formulations_AAPSWorkshop

19

Notes on surfactants

• Ethoxylated surfactants can be synthesised by direct reaction with ethylene oxide, or by esterification reactions with PEG.

• Many commonly used triglyceride ethoxylates are formed by hydrolysis of triglycerides and then esterification with PEG. This results in a wide range of molecules: free oils, ethoxylated TGs, ethoxylated DGs, ethoxylated MGs, ethoxylated glycerol, free PEG, all of which are polymeric

• As a result Labrosol, Labrafils, Gelucires, Cremophor RH40 and EL contain hundreds of individual molecules. Polysorbates are much less heterogeneous.

• Labrasol (medium chain ethoxylate) acts like a formulated SEDDS when introduced to water (ie. oil, cosurfactant, surfactant, cosolvent –all in one excipient).

• Poloxamers are good quality materials but their molecular weight makes them less mobile and reduces their performance as self-emulsifying systems

Page 20: Excipients fpr lipid formulations_AAPSWorkshop

20

Surfactants: Polyethoxylated lipids

• Many of the surfactant systems used in contemporary lipid based formulations are variations on a theme of polyethoxylated lipids

• The lipids may be fatty acids, alcohols or glycerides and are linked to any number of repeating polyethylene oxide units typically by ester links (glycerides, fatty acids), and occasionally by ether linkages (alcohols)

• Although the hydrophilic group is often PEG, this is not always the case, and can be other glycols etc

Page 21: Excipients fpr lipid formulations_AAPSWorkshop

21

General Schematic: Surfactant production

• Products obtained by esterification of vegetable fats or oils or fatty acids with glycols, polyethylene glycols or alcohols, or alternatively by reaction of fatty acids, fatty alcohols with oxyethylene

• Raw materials from vegetable origin

• Combination of a hydroxyl group substrate with an alkyl tail

Fatty acids or glycerideswith various lengths: Caprylate, caprylic, lauric, stearic, ..

Lipophilic Chain

PEGPropylene glycolGlycerol

Hydrophilic head group

Provides the amphiphilicity of surfactants

Page 22: Excipients fpr lipid formulations_AAPSWorkshop

22

Polyethoxylated fatty acid esters, e.g. Myrj

Myrj 45

PEG 400 monostearate

Polyoxy 8 stearate

R-C-(O-CH2-CH2)n-OH

O

Name R (fatty acid) PEG mol wt n HLB

Stearic (C18) acid 400 8 11.1

Solutol HS 15

PEG 660 hydroxy-stearate

Macrogol 15 hydroxy-stearate

12-hydroxystearic (C18) acid

660 15 14-16

Page 23: Excipients fpr lipid formulations_AAPSWorkshop

23

Polyethoxylated alkyl ethers, e.g. Brij

R-(O-CH2-CH2)n-OH

Name R (alcohol) PEG mol wt n HLB

Oleyl (C18:1) ~450 10 12.4Brij 97

Polyoxyl 10 oleyl ether

Oleth 10

PEG monooleyl ether

Stearic (C18) and Cetyl (C16)

~1100 25 15-17Cremophor A 25

Macrogol 25 cetostearyl ether

(Cetomacrogol)

Page 24: Excipients fpr lipid formulations_AAPSWorkshop

24

Polyethoxylated sorbitan esters (polysorbates) e.g. Tweens

Name R (fatty acid) POEn HLB

Oleyl (C18:1)

trioleyl (C18:1)

20

20

15.0

11.5

Tween 80

Tween 85

Page 25: Excipients fpr lipid formulations_AAPSWorkshop

25

Polyethoxylated glycerides: e.g. Cremophor

Name R (fatty acid) PEG mol wt n

Castor oil - TG of ricinoleic acid (12-

hydroxyoleic acid)

1600 35 12-14

Cremophor EL

Polyoxyl 35 Castor oil

Glycerol polyethylene glycol ricinoleate

R is ricinoleic acid based glycerides (ie from castor oil). The PEG chain is linked to side OH groups of the ricinoleate chains.

Hydrogenated Castor oil - TG of oxystearic acid

1600 40 14-16

Cremophor RH 40

Polyoxyl 40 hydro-genated castor oil

Glycerol polyethylene glycol oxystearate

HLB

Also contains mono, di and triglycerides, and some free PEG

Page 26: Excipients fpr lipid formulations_AAPSWorkshop

26

Polyethoxylated glycerides: e.g. Labrafils

Name R (fatty acid) PEG mol wt n

Mixed glycerides of

C18:1 - 58-80%

C18:2 – 15-35%

C16 – 4-9%

C18 - <6%

300 6 4

Labrafil M 1944

PEG 300 oleic glycerides

Oleoyl Macrogol-6 glycerides

HLB

Formed by esterification of PEG 300 and apricot kernel oil.

Labrafil is composed of tri and partial glycerides and esters of PEG 300

Both also contain mono, di and triglycerides, and some free PEG

As above but greater C18:2composition

300 6 4

Labrafil M 2125

PEG 300 linoleicglycerides

Linoleoyl Macrogol-6-glycerides

Page 27: Excipients fpr lipid formulations_AAPSWorkshop

27

Polyethoxylated glycerides: e.g. Labrasol

Name R (fatty acid) PEG mol wt n

Mixed glycerides of

C8 - 50-80%

C10 – 20-50%

C12 – < 3%

C18 - <6%

400 8 14

Labrasol

PEG 8 caprylic/capric glycerides

Caprylcaproylpolyoxyglycerides

HLB

Also contains some free PEG

Formed by esterification of PEG 400 and medium chain triglyceride oil.

Labrasol is composed of tri and partial glycerides and esters of PEG 400

Page 28: Excipients fpr lipid formulations_AAPSWorkshop

28

Waxy Polyethoxylated glycerides: e.g. Gelucire 44/14

Name R (fatty acid) PEG mol wt n

Mixed glycerides of

C12 – 40-50%

C14 – 14-24%

C8 – 4-10%

C10 – 3-9%

C16 – 4-14%

C18 – 5-15%

1500 32 14

Gelucire 44/14

hydrogenated palm kernel oil PEG-32 esters

lauryl polyoxyglycerides

lauryl macrogolglycerides

HLB

Formed by esterification of PEG 1500 and hydrogenated palm kernel oil

Gelucire 44/14 is composed of partial glycerides and esters of PEG 1500

Nomenclature: HLB/Mpt eg 44/14

Page 29: Excipients fpr lipid formulations_AAPSWorkshop

29

Polyethoxylated glycerides: e.g. Gelucire 50/13

Name R (fatty acid) PEG mol wt n

Mixed glycerides of

C16 – 40-50%

C18 – 48-58%

C16+18 - >90%

1500 32 13

Gelucire 50/13

stearoylpolyoxyglycerides

stearylmacrogolglycerides

HLB

Formed by esterification of PEG 1500 and hydrogenated palm oil

Gelucire 50/13 is composed of partial glycerides and esters of PEG 1500

Nomenclature: Mpt/HLB eg 50/13

Page 30: Excipients fpr lipid formulations_AAPSWorkshop

30

Poly-glycerol esters: e.g. Plurol Oleique

Plurol Oleique CC497; (polyglyceryl-3-dioleate)

Diesters of oleic acid with a glycerin polymer (containing n=3 repeating glycerin units)

HLB = 6

Plurol Oleique (polyglyceryl-6-dioleate)

Diesters of oleic acid with a glycerin polymer (containing n=6 repeating glycerin units)

HLB = 10

1o Oral applications, Pharma grade

1o cosmetic or topical pharma applications

OH-(CH2-CH-CH2-O-)nH

OH Primarily di- and tri-oleic acid esters of polyglcerolR-C-O-

O

Page 31: Excipients fpr lipid formulations_AAPSWorkshop

31

TPGS and poloxamers

TPGS: D-a-tocopheryl PEG 1000 succinate (MW = 1513)

Formed as esterification product between acid group of Vit E and PEG 1000

Used as an emulsifier (HLB ~13)

Also possible effects on eg P-gp efflux

General structure of poloxamers

Page 32: Excipients fpr lipid formulations_AAPSWorkshop

32

Cosolvents

C2H5-O-CH2-CH2-O-CH2-CH2-OH

Diethylene glycol monoethyl ether (Transcutol)

Propylene glycol

Polyethylene glycol (PEG), polyoxyethylene

Ethanol

Propylene carbonate

Glycofurol (tetrahydrofurfuryl alcohol polyethylene glycol ether)

Page 33: Excipients fpr lipid formulations_AAPSWorkshop

Acknowledgements

University of Bath, UKMark WakerlyDebbie ChallisLinda SolomonNaser HasanRajaa Al Sukhun

Victorian College of PharmacyDallas WarrenKazi MohsinJean Cuine Chris Porter Bill Charman

R P Scherer Ltd. digestion experiments 1991-1994

Cardinal Healthmolecular dynamics modeling 2002-2004

Abbott Laboratoriesrecent formulation work 2002-2006

Capsugelin vitro-in vivo correlation 2003-2006Support for LFCS